SCHEMBL6023158

SCHEMBL6023158

CCCCOc1cc(C=CC(=O)N2CCN(CC(O)c3ccc(OC)cc3)CC2)cc(OCCCC)c1O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP3A4 P08684 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.48
MEN1 O00255 1/20 0.46
THRB P10828 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR183 P32249 3/20 0.44
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
ADRB3 P13945 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
IGF1R P08069 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023915 0.97 MEN1 (0.50) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023886 0.92 KDM4E (0.45) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023118 0.91 KDM4E (0.52) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023365 0.91 KDM4E (0.45) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023327 0.91 ACHE (0.48) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6022737 0.90 KDM4E (0.49) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6022960 0.89 MEN1 (0.49) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023973 0.88 KDM4E (0.51) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6023506 0.88 MEN1 (0.47) ACHEKDM4ECYP3A4HPGDCYP2C19
SCHEMBL6022925 0.88 MEN1 (0.47) ACHEKDM4ECYP3A4HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078407-B2 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-07-18 US claimed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US claimed
US-7078407-B2 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-07-18 US disclosed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them HTT, PARK7, NQO1 ACHE 233/4885KDM4E 1388/4885CYP3A4 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.